Cullinan Associates Inc. Decreases Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cullinan Associates Inc. decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 23.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,900 shares of the medical equipment provider’s stock after selling 1,500 shares during the period. Cullinan Associates Inc.’s holdings in Intuitive Surgical were worth $2,545,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the period. Capital World Investors grew its position in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after purchasing an additional 73,634 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Intuitive Surgical by 4.6% during the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after purchasing an additional 198,483 shares during the period. American Century Companies Inc. lifted its holdings in Intuitive Surgical by 3.0% during the 2nd quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock worth $1,066,837,000 after purchasing an additional 70,556 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its stake in Intuitive Surgical by 1.6% in the 2nd quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock worth $881,380,000 after purchasing an additional 30,449 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $446.60, for a total transaction of $167,921.60. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,458,979.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 52,192 shares of company stock valued at $25,398,571 over the last three months. 0.90% of the stock is owned by company insiders.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. Citigroup raised their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Piper Sandler reissued an “overweight” rating and set a $538.00 price objective (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Morgan Stanley boosted their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. Finally, Robert W. Baird boosted their price target on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded down $0.16 during trading hours on Friday, reaching $511.47. The company had a trading volume of 87,714 shares, compared to its average volume of 1,465,155. The firm has a market cap of $181.42 billion, a price-to-earnings ratio of 92.35, a P/E/G ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $523.34. The company has a 50-day moving average price of $486.71 and a 200 day moving average price of $440.96.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.